Shares in Insulet (NSDQ:PODD) rose today after the company met earnings expectations on Wall Street and beat sales estimates with its second quarter results.
The Billerica, Mass.-based company posted a net loss of -$7.8 million, or -13¢ per share, on sales of $109.8 million for the 3 months ended June 30, for bottom-line loss of -85% on sales growth of 26% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet Q2 sales tops estimates appeared first on MassDevice.